Senator Joseph I. Lieberman Co-Authors “Russian Aggression Underscores the U.S.’s Need for Greater Investment in Medical Countermeasures”
Kasowitz Benson Torres senior counsel Senator Joseph I. Lieberman and Dr. Michelle McMurry-Heath, CEO and President of the Biotechnology Innovation Organization (BIO), have co-authored “Russian Aggression Underscores the U.S.’s Need for Greater Investment in Medical Countermeasures,” published in STAT. In the article, the authors discuss, in the wake of Russia’s threat to use chemical weapons against Ukraine, why America needs to invest in innovative medical countermeasures and what the U.S. government can do so it is ready to respond to any chemical, biological, radiological, and nuclear threats.
Senator Joseph I. Lieberman, senior counsel at Kasowitz Benson Torres, represents clients in independent and internal investigations and advises them on a wide range of public policy, strategic and regulatory issues. He also assists corporate clients on homeland and national security and defense matters. During Senator Joseph Lieberman’s tenure as a United States Senator, he helped shape legislation concerning national and homeland security. In addition, he served in many leadership roles, including Chairman of the Committee on Homeland Security and Government Affairs. Since 2014, Senator Lieberman has co-chaired the Bipartisan Commission on Biodefense.
Dr. Michelle McMurry-Heath is the president and CEO of the Biotechnology Innovation Organization, which supports companies that discover and deploy scientific breakthroughs that improve human health, environmental stewardship, and sustainable agriculture.